MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)。

Fluvoxamine

產(chǎn)品活性：Fluvoxamine (DU-23000) 是5-羥色胺再吸收抑制劑，有抗抑郁活性。

研究領(lǐng)域：Neuronal Signaling

作用靶點(diǎn)：Serotonin Transporter

In Vivo: Fluvoxamine (DU-23000) is effective in inhibiting 5-ht uptake by blood platelets and brain synaptosomes. The antagonism by fluvoxamine of the reserpine-induced lowering of the pentamethylenetetrazole convulsive threshold can be regarded as due to an effect upon 5-HT uptake. In contrast to the effects of desmethylimipramine and imipramine, no stimulatory effects are found in rats when rapidly acting reserpine-like compounds are given following a dose of fluvoxamine. Fluvoxamine (DU-23000) appears to improve combat-related PTSD symptoms but not depressive symptoms. The high attrition rate and lack of a placebo group limits the conclusions of our study. Controlled studies of fluvoxamine in the treatment of PTSD are warranted. Fluvoxamine (DU-23000) was less potent at decreasing ethanol self-administration when food was available concurrently versus when ethanol was available in isolation [ED50: 4.0 (2.7-5.9) and 5.1 (4.3-6.0)]. Effects on food were similar under each condition in which food was available. The results demonstrate that the potency of fluvoxamine in reducing ethanol-maintained behavior depends on whether ethanol is available in isolation or in the context of concurrently scheduled food reinforcement.

相關(guān)產(chǎn)品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Neuronal Signaling Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Antiviral Compound Library  |  Drug Repurposing Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Antidepressant Compound Library  |  FDA-Approved Anticancer Drug Library  |  Human Metabolite Library  |  Coagulation and Anti-coagulation Compound Library  |  Off-patent Drug Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Bupropion-d₉ (hydrochloride)  |  Vortioxetine hydrobromide  |  SERT-IN-2  |  Venlafaxine-d₆  |  Dapoxetine  |  rel-Paroxetine-d₄ (hydrochloride)  |  DSP-1053 benzenesulfonate  |  Desvenlafaxine-d₁₀  |  Norfenfluramine  |  Eplivanserin (mixture)  |  Desvenlafaxine-d₆  |  Indalpine  |  Vortioxetine-d₈ (hydrobromide)  |  Bupropion hydrobromide  |  (±)-Duloxetine-d₇  |  Desipramine-d₄  |  Centanafadine  |  Escitalopram  |  Desmethyl Sibutramine hydrochloride  |  Dextromilnacipran  |  Azaphen dihydrochloride monohydrate  |  Wf-516  |  Nitroxazepine  |  SPD-473 citrate  |  Amitriptyline-d₆ (hydrochloride)  |  Ansofaxine  |  Fluvoxamine maleate  |  (±)-Duloxetine hydrochloride

品牌介紹:
•   MCE (MedChemExpress) 擁有200 多種*僅有化合物庫(kù)，我們致力于為*科研客戶提供前沿的高品質(zhì)小分子活性化合物；
•   50,000 多種高選擇性抑制劑、激動(dòng)劑涉及各熱門信號(hào)通路及疾病領(lǐng)；
•   產(chǎn)品種類涵蓋各種重組蛋白，多肽，常用試劑盒 ，更有 PROTAC、ADC 等特色產(chǎn)品，廣泛應(yīng)用于新藥研發(fā)、生命科學(xué)等科研項(xiàng)目；
•   提供虛擬篩選，離子通道篩選，代謝組學(xué)分析檢測(cè)分析，藥物篩選等專業(yè)技術(shù)服務(wù)；
•   設(shè)有專業(yè)的實(shí)驗(yàn)中心和嚴(yán)格的質(zhì)控、驗(yàn)證體系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項(xiàng)質(zhì)檢報(bào)告，確保產(chǎn)品的高純度、高品質(zhì)；
•   產(chǎn)品的生物活性多經(jīng)各國(guó)客戶實(shí)驗(yàn)驗(yàn)證；
•   Nature, Cell, Science 等多種頂級(jí)期刊及制藥 Patent 收錄了MCE客戶的科研成果；
•   專業(yè)團(tuán)隊(duì)跟蹤新的制藥及生命科學(xué)研究進(jìn)展，為您提供*新的活性化合物；
•   與世界各大制藥公司及*科研機(jī)構(gòu)建立了長(zhǎng)期的合作。